24
Participants
Start Date
January 20, 2021
Primary Completion Date
December 14, 2023
Study Completion Date
December 14, 2023
MOR202
MOR202 will be administered as an intravenous infusion
Managadze National Center of Urology, Tbilisi
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi
University Hospital Aachen, Aachen
Charite, Berlin
DaVita Clinical Research, Düsseldorf
Uniklinikum, Essen
Hospital of Johannes Gutenberg University, Mainz
General Hospital of Athens, Athens
General Hospital of Heraklion Venizeleio-Papaneio, Heraklion
University General Hospital of Patras, Pátrai
General Hospital of Thessaloniki, Thessaloniki
Botkin Hospital Moscow, Moscow
First Pavlov State Medical University of St. Petersburg, Saint Petersburg
Hallym University Sacred Heart Hospital, Chuncheon
JeJu National University Hospital, Jeju City
Konkuk University Hospital, Seoul
Kyung Hee University Hospital at Gangdong, Seoul
Seoul National University Bundang Hospital, Seoul
Chang Gung Memorial Hospital, Kaohsiung City
Shuang Ho Hospital, New Taipei City
China Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
National Taiwan University Hospital, Taipei
Kings College, London
Nottingham Renal and Transplant Unit, Nottingham
HI-Bio, A Biogen Company
INDUSTRY